ALN-VSP phase I trial: demographics and dosing
| Total study population, N | 41 |
| Dose escalation (0.1–1.5 mg/kg) | 30 |
| Expansion phase at 1.0 and 1.25 mg/kg | 11 (6 at 1.0 mg/kg, 5 at 1.25 mg/kg) |
| Median age | 57 (range, 34–78) |
| Male:female | 17:24 |
| ECOG performance status 0/1, % | 44/56 |
| Average number of prior regimens for metastatic disease | 4.3 (range, 0–15) |
| Prior chemotherapy/anti-VEGF therapy, % | 88/61 |
| Liver/extrahepatic metastases, % | 98/88 |
| Tumor types, N | |
| Gastrointestinal | 24 |
| Gynecological | 9 |
| Genitourinary | 3 |
| Sarcoma | 2 |
| Other | 3 |
| Doses administered | 277 |
| Average number of doses/patient | 6.8 (range, 1–50) |
Abbreviation: ECOG, Eastern Cooperative Oncology Group.